Pub Date : 2021-12-23DOI: 10.4274/vhd.galenos.2021.2021-1-3
F. Tabak, G. Sirin, M. Demir, M. Aladağ, Ş. Sümer, B. Kurtaran, S. Tosun, T. Yamazhan, İlkay Bozkurt, Yunus Gürbüz, A. Batırel, E. Şenateş, F. O. Kandemir, Firdevs Topal, H. Doğanay, O. Sezgin, R. Mıstık, Ş. Köse, Y. Yılmaz, D. Inan, İ. Köksal, E. Parlak, M. Akdoğan, Rahmet Güner
ÖZ Objectives: To describe the prevalence of risk factors in patients infected with hepatitis C virus (HCV). Materials and Methods: Patients who were aged >18 years visiting outpatient clinics and diagnosed as having HCV infection were enrolled in this cross-sectional, multicenter study conducted in 71 cities. Patient data on socio-demographic and clinical characteristics and pre-defined risk factors were collected. Results: Among 1,018 patients, 53.0% were women. The mean age was 57.2±14.3 years and 34.8% had been diagnosed as having HCV infection >10 years before enrollment. Almost half of the patients (45.5%) were diagnosed during their regular check-up visits, and only 16.8% were diagnosed because of signs or symptoms of HCV. Genotype 1 and sub-genotype 1 b were detected in 87.9% and 73.7% of the patients, respectively. At least one risk factor was present in 94.8% of the patients. The most frequently reported risk factor was major dental procedures (79.2%), followed by major surgical operations (56.9%) and minor surgical interventions (42.3%). Conclusion: Our results revealed that most of the patients with HCV infection underwent major dental procedures.
{"title":"Demographic Characteristics and Transmission Risk Factors of Patients with Hepatitis C Virus in Turkey: The EPI-C, A Multicenter and Cross-sectional Trial","authors":"F. Tabak, G. Sirin, M. Demir, M. Aladağ, Ş. Sümer, B. Kurtaran, S. Tosun, T. Yamazhan, İlkay Bozkurt, Yunus Gürbüz, A. Batırel, E. Şenateş, F. O. Kandemir, Firdevs Topal, H. Doğanay, O. Sezgin, R. Mıstık, Ş. Köse, Y. Yılmaz, D. Inan, İ. Köksal, E. Parlak, M. Akdoğan, Rahmet Güner","doi":"10.4274/vhd.galenos.2021.2021-1-3","DOIUrl":"https://doi.org/10.4274/vhd.galenos.2021.2021-1-3","url":null,"abstract":"ÖZ Objectives: To describe the prevalence of risk factors in patients infected with hepatitis C virus (HCV). Materials and Methods: Patients who were aged >18 years visiting outpatient clinics and diagnosed as having HCV infection were enrolled in this cross-sectional, multicenter study conducted in 71 cities. Patient data on socio-demographic and clinical characteristics and pre-defined risk factors were collected. Results: Among 1,018 patients, 53.0% were women. The mean age was 57.2±14.3 years and 34.8% had been diagnosed as having HCV infection >10 years before enrollment. Almost half of the patients (45.5%) were diagnosed during their regular check-up visits, and only 16.8% were diagnosed because of signs or symptoms of HCV. Genotype 1 and sub-genotype 1 b were detected in 87.9% and 73.7% of the patients, respectively. At least one risk factor was present in 94.8% of the patients. The most frequently reported risk factor was major dental procedures (79.2%), followed by major surgical operations (56.9%) and minor surgical interventions (42.3%). Conclusion: Our results revealed that most of the patients with HCV infection underwent major dental procedures.","PeriodicalId":42346,"journal":{"name":"Viral Hepatit Dergisi-Viral Hepatitis Journal","volume":" ","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48341537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-23DOI: 10.4274/vhd.galenos.2021.2021-6-1
M. Pekgöz, N. Ince
Objectives: Chronic hepatitis C virus (HCV) is a fundamental worldwide health challenge. We assessed the treatment outcomes of ledipasvir (LDV) and sofosbuvir (SOF) with and without ribavirin (RBV) for 12 and 24 weeks in pre-treated and treatment-naive patients with chronic HCV. Materials and Methods: Totally 65 patients were included in the present study. Patients were divided in two groups. In the first group, LDV and SOF with RBV were administered to 12 patients for 12 weeks. In the second group, LDV and SOF without RBV were administered to 53 patients for 24 weeks. Results: Sustained virological response (SVR) rates were 100% for the both groups included in the study. The adverse events were weakness (15.39%), pruritus (6.15%), myalgia (4.62%) nausea (3.08%), dry mouth (1.54%) and anorexia (1.54%) in all patients. HCV-RNA was also negative in all patients 48 weeks after the beginning of the treatment. At the end of the fifth year of treatment, all the patients still had SVR and no recurrence was detected. Conclusion: In the treatment of patients with chronic HCV, LDV and SOF with and without RBV were highly effective. SVR rate of 100% was achieved in all pre-treated or treatment naive patients with or without cirrhosis regardless of genotype of HCV.
{"title":"The Treatment of Ledipasvir/Sofosbuvir in Patients with Chronic Hepatitis C Virus: The Results of Five-year Follow-up","authors":"M. Pekgöz, N. Ince","doi":"10.4274/vhd.galenos.2021.2021-6-1","DOIUrl":"https://doi.org/10.4274/vhd.galenos.2021.2021-6-1","url":null,"abstract":"Objectives: Chronic hepatitis C virus (HCV) is a fundamental worldwide health challenge. We assessed the treatment outcomes of ledipasvir (LDV) and sofosbuvir (SOF) with and without ribavirin (RBV) for 12 and 24 weeks in pre-treated and treatment-naive patients with chronic HCV. Materials and Methods: Totally 65 patients were included in the present study. Patients were divided in two groups. In the first group, LDV and SOF with RBV were administered to 12 patients for 12 weeks. In the second group, LDV and SOF without RBV were administered to 53 patients for 24 weeks. Results: Sustained virological response (SVR) rates were 100% for the both groups included in the study. The adverse events were weakness (15.39%), pruritus (6.15%), myalgia (4.62%) nausea (3.08%), dry mouth (1.54%) and anorexia (1.54%) in all patients. HCV-RNA was also negative in all patients 48 weeks after the beginning of the treatment. At the end of the fifth year of treatment, all the patients still had SVR and no recurrence was detected. Conclusion: In the treatment of patients with chronic HCV, LDV and SOF with and without RBV were highly effective. SVR rate of 100% was achieved in all pre-treated or treatment naive patients with or without cirrhosis regardless of genotype of HCV.","PeriodicalId":42346,"journal":{"name":"Viral Hepatit Dergisi-Viral Hepatitis Journal","volume":" ","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47011319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-23DOI: 10.4274/vhd.galenos.2021.2021-5-6
M. Mahmood, M. A. Anwar, Muhammad Naseem Hasrat, Zahid Azam
{"title":"Effect of Hepatitis B Virus Genotypes and Viral Load on the Response of Patients Treated with Peginterferon-αα-2a","authors":"M. Mahmood, M. A. Anwar, Muhammad Naseem Hasrat, Zahid Azam","doi":"10.4274/vhd.galenos.2021.2021-5-6","DOIUrl":"https://doi.org/10.4274/vhd.galenos.2021.2021-5-6","url":null,"abstract":"","PeriodicalId":42346,"journal":{"name":"Viral Hepatit Dergisi-Viral Hepatitis Journal","volume":" ","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43504725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-23DOI: 10.4274/vhd.galenos.2021.2021-5-5
M. Mahmood, Sdia Jameel, Z. Rahman, M. A. Anwar
Objectives: Current study was designed to screen out the resistant mutations in reverse transcriptase (RT) domain of hepatitis B virus (HBV) genome from non-responder Pakistani patients. Materials and Methods: A total of 22 patients, receiving different nucleot(s)ide analogues were included in the study. RT domain of the virus from samples of non-responder patients was amplified and sequenced. Sequences were aligned and analyzed for RT domain mutations. Results: After 18 months, 18 patients were responder and 4 were non-responder. Mean alanine aminotransferase (ALT) and viral load of responder patients decreased significantly as compared to those of non-responder patients. Two of the 4 samples from nonresponders were successfully sequenced. Mutations rtY135S, rtI169P, rtV173P, rtL180I, rtA181V, rtT184Y and rtM204V were identified from the sample of patient 1, while rtL80V/rtL80G and rtY135S were identified from the sample of patient 2. Conclusion: Mutations rtY135S, rtI169P, rtV173P, rtL180I, rtA181V, rtT184Y, rtM204V, rtL80V/rtL80G, and rtY135S are present in genome of HBV circulating in Pakistani patients. These mutations give resistance to virus against lamivudine, telbivudine, adefovir, and partially resistance against entecavir. However, no mutation was found to be associated with the viral resistance against tenofovir.
{"title":"Molecular Analysis of Hepatitis B Virus Reverse Transcriptase Domain for Mutations Associated with Viral Resistance in Pakistani Patients","authors":"M. Mahmood, Sdia Jameel, Z. Rahman, M. A. Anwar","doi":"10.4274/vhd.galenos.2021.2021-5-5","DOIUrl":"https://doi.org/10.4274/vhd.galenos.2021.2021-5-5","url":null,"abstract":"Objectives: Current study was designed to screen out the resistant mutations in reverse transcriptase (RT) domain of hepatitis B virus (HBV) genome from non-responder Pakistani patients. Materials and Methods: A total of 22 patients, receiving different nucleot(s)ide analogues were included in the study. RT domain of the virus from samples of non-responder patients was amplified and sequenced. Sequences were aligned and analyzed for RT domain mutations. Results: After 18 months, 18 patients were responder and 4 were non-responder. Mean alanine aminotransferase (ALT) and viral load of responder patients decreased significantly as compared to those of non-responder patients. Two of the 4 samples from nonresponders were successfully sequenced. Mutations rtY135S, rtI169P, rtV173P, rtL180I, rtA181V, rtT184Y and rtM204V were identified from the sample of patient 1, while rtL80V/rtL80G and rtY135S were identified from the sample of patient 2. Conclusion: Mutations rtY135S, rtI169P, rtV173P, rtL180I, rtA181V, rtT184Y, rtM204V, rtL80V/rtL80G, and rtY135S are present in genome of HBV circulating in Pakistani patients. These mutations give resistance to virus against lamivudine, telbivudine, adefovir, and partially resistance against entecavir. However, no mutation was found to be associated with the viral resistance against tenofovir.","PeriodicalId":42346,"journal":{"name":"Viral Hepatit Dergisi-Viral Hepatitis Journal","volume":" ","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49029935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-08-01DOI: 10.4274/vhd.galenos.2021.2021-2-6
A. Kaya, S. Kaya, B. Mete, I. Balkan, N. Saltoğlu, Ö. Tabak
{"title":"Insulin Resistance in Patients with Chronic Hepatitis B Virus Infection: A Case-control Study","authors":"A. Kaya, S. Kaya, B. Mete, I. Balkan, N. Saltoğlu, Ö. Tabak","doi":"10.4274/vhd.galenos.2021.2021-2-6","DOIUrl":"https://doi.org/10.4274/vhd.galenos.2021.2021-2-6","url":null,"abstract":"","PeriodicalId":42346,"journal":{"name":"Viral Hepatit Dergisi-Viral Hepatitis Journal","volume":" ","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47892069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-08-01DOI: 10.4274/vhd.galenos.2021.2021-3-1
S. Tosun, Ayşe Albayrak, G. Durmus, İrem Çetin Altaş, Ayşegül Özel, N. Tülek, A. Kadanalı, S. Erol, Arzu Altunçekiç Yıldırım, N. Ceran, Ö. Dağlı, A. Olut
{"title":"The Etiology and Clinical Follow-up of Patients with Acute Viral Hepatitis in an Adult Population: A Prospective Multicenter Study","authors":"S. Tosun, Ayşe Albayrak, G. Durmus, İrem Çetin Altaş, Ayşegül Özel, N. Tülek, A. Kadanalı, S. Erol, Arzu Altunçekiç Yıldırım, N. Ceran, Ö. Dağlı, A. Olut","doi":"10.4274/vhd.galenos.2021.2021-3-1","DOIUrl":"https://doi.org/10.4274/vhd.galenos.2021.2021-3-1","url":null,"abstract":"","PeriodicalId":42346,"journal":{"name":"Viral Hepatit Dergisi-Viral Hepatitis Journal","volume":" ","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44241217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-08-01DOI: 10.4274/vhd.galenos.2021.2020-12-8
Emine Füsun Karaşahin1, Ömer Karaşahin, İ. Akdemir Kalkan
{"title":"Results of Viral Hepatitis and Human Immunodeficiency Virus Screening in Afghan Irregular Migrants: A Crosssectional Study (2011-2019)","authors":"Emine Füsun Karaşahin1, Ömer Karaşahin, İ. Akdemir Kalkan","doi":"10.4274/vhd.galenos.2021.2020-12-8","DOIUrl":"https://doi.org/10.4274/vhd.galenos.2021.2020-12-8","url":null,"abstract":"","PeriodicalId":42346,"journal":{"name":"Viral Hepatit Dergisi-Viral Hepatitis Journal","volume":" ","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47546800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-08-01DOI: 10.4274/vhd.galenos.2021.2020-12-4
A. Kaya Kalem, Rahmet Güner, F. Eser, I. Hasanoğlu, G. Yılmaz, Mehmet Akın Taşyaran
{"title":"Evaluation of Knowledge Levels, Attitudes and Behaviors Among the Relatives of Patients Infected with Hepatitis B","authors":"A. Kaya Kalem, Rahmet Güner, F. Eser, I. Hasanoğlu, G. Yılmaz, Mehmet Akın Taşyaran","doi":"10.4274/vhd.galenos.2021.2020-12-4","DOIUrl":"https://doi.org/10.4274/vhd.galenos.2021.2020-12-4","url":null,"abstract":"","PeriodicalId":42346,"journal":{"name":"Viral Hepatit Dergisi-Viral Hepatitis Journal","volume":" ","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44223096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：